Charles Schwab Investment Management Inc. Acquires 2,301 Shares of Grifols, S.A. (NASDAQ:GRFS)

Charles Schwab Investment Management Inc. increased its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 7.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,543 shares of the biotechnology company’s stock after purchasing an additional 2,301 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Grifols were worth $280,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. GAMMA Investing LLC raised its position in Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after buying an additional 1,135 shares during the last quarter. Signaturefd LLC grew its stake in shares of Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 2,153 shares during the period. AQR Capital Management LLC purchased a new position in shares of Grifols during the second quarter valued at approximately $89,000. Chesapeake Capital Corp IL bought a new position in Grifols during the third quarter valued at approximately $148,000. Finally, Creative Planning boosted its holdings in Grifols by 26.4% in the third quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 3,614 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Stock Up 3.9 %

Grifols stock opened at $7.72 on Friday. Grifols, S.A. has a one year low of $5.30 and a one year high of $12.15. The stock has a fifty day moving average of $8.37 and a 200 day moving average of $8.10. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The stock has a market cap of $5.31 billion, a PE ratio of 7.96 and a beta of 0.43.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.